SCHEMBL6020562

SCHEMBL6020562

CCN(C#N)C(=O)C(Cc1ccccc1)NC(=O)NC12CC3CC(CC(C3)C1)C2

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 8/20 0.50
F10 P00742 1/20 0.50
MAPK1 P28482 1/20 0.49
EPHX1 P07099 2/20 0.45
LMNA P02545 1/20 0.44
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
CPB2 Q96IY4 1/20 0.42
CYP2D6 P10635 1/20 0.42
MAPT P10636 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6020638 0.91 EPHX2 (0.50) EPHX2F10MAPK1LMNACTSL
SCHEMBL6021305 0.89 MMP9 (0.43) EPHX2F10MAPK1LMNACTSL
SCHEMBL6020451 0.83 CTSL (0.43) EPHX2F10MAPK1CTSLCTSS
SCHEMBL6020665 0.83 EPHX2 (0.55) EPHX2CTSLCTSSCTSKKMT2A
SCHEMBL6021501 0.82 EPHX2 (0.41) EPHX2EPHX1LMNAALDH1A1HTT
SCHEMBL6020635 0.81 F10 (0.63) EPHX2F10MAPK1EPHX1CTSL
SCHEMBL6021134 0.81 ATM (0.58) LMNACTSLCTSBCTSSCTSK
SCHEMBL6019817 0.79 EPHX2 (0.38) EPHX2EPHX1LMNAALDH1A1HTT
SCHEMBL6020216 0.78 CTSK (0.60) CTSLCTSBCTSSCTSK
SCHEMBL6020100 0.78 EPHX2 (0.44) EPHX2LMNACTSLCTSBCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060252813-A1 Apparatus for curing a composite laminate JERINI AG (DE) 2006-11-09 US claimed
WO-2004056755-A2 COMPOUNDS FOR THE INHIBITION OF NON-PROTEOLYTIC ENZYMES JERENI AG (DE) 2004-07-08 WO claimed
EP-1433778-A1 Use of nitriles as rotamase inhibitors Jerini AG (DE) 2004-06-30 EP claimed
EP-1433779-A1 Use of nitriles as inhibitors of non-proteolytic enzymes Jerini AG (DE) 2004-06-30 EP claimed
US-20060252813-A1 Apparatus for curing a composite laminate JERINI AG (DE) 2006-11-09 US disclosed
EP-1575903-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES Jerini AG (DE) 2005-09-21 EP disclosed
WO-2004065353-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES JERINI AG (DE) 2004-08-05 WO disclosed
WO-2004056755-A2 COMPOUNDS FOR THE INHIBITION OF NON-PROTEOLYTIC ENZYMES JERENI AG (DE) 2004-07-08 WO disclosed
EP-1433778-A1 Use of nitriles as rotamase inhibitors Jerini AG (DE) 2004-06-30 EP disclosed
EP-1433779-A1 Use of nitriles as inhibitors of non-proteolytic enzymes Jerini AG (DE) 2004-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252813-A1 Apparatus for curing a composite laminate DHX29, HDHD5, DHRS9 EPHX2 8/4885F10 2907/4885MAPK1 4315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.